Back

Pharma

2nd Annual Biosimilars Summit

  • 8th – 9th February 2016
  • Germany flag Germany Berlin
  • Kempinski Hotel Bristol Kurfürstendamm 27, 10719

This innovative B2B event will enable the participants to learn about the latest trends of the Biosimilars, commercialization aspects, regulatory advises and strategies for Biosimilars development.

Read more

About

This innovative B2B event will enable the participants to learn about the latest trends of the Biosimilars, commercialization aspects, regulatory advises and strategies for Biosimilars development. As biosimilars are now being developed and manufactured using todays state of the art technology and techniques, they can potentially also offer some benefits, in addition to cost, over the reference biologics. It is proved that Biosimilars could save the U.S. health system close to $44 billion in the next ten years.

#BiosimilarsBerlin

Who Should Attend

Chief Executives, Executive Directors, VPs, Department Heads, Team Leaders and Managers from:

  • Biologics/Biotechnology/ Biogenerics
  • Legal Affairs
  • Pricing and Reimbursement
  • Regulatory Compliance
  • Preclinical and Clinical Development
  • Quality Affairs/ Quality Control
  • Biopharmaceuticals
  • Intellectual property
  • Clinical Immunology
  • R&D
  • New Product Development
  • Pharmacovigilance

From Industries Including:

  • Clinical Immunology
  • Immunology
  • Drug Safety
  • Preclinical Development
  • Therapeutic Areas
  • Business Development
  • Vaccines Development
  • Scientific Affairs
  • Global Strategy
  • Antibody Engineering
  • Oncology
  • Infection and Immunity
  • Risk Management
  • Clinical Program
  • Personalized Medicine
  • Portfolio Planning
  • Regulatory Affairs
  • Validation
  • Analytical Characterization
  • Antibody Discovery

Key Practical Learning Points

  • The latest trends of the biosimilars
  • Successful commercialization of biosimilars in Europe and USA
  • Biosimilars in emerging markets – Regulatory and commercial considerations
  • Industry partnerships: Key success factor to win in biosimilar space
  • Regulatory advice on designing biosimilar trials
  • Totality of evidence and what it means to clinician
  • Experience of global clinical biosimilar trials
  • Strategies and competing products for a successful commercialization

Dr. Jakob Lange, CH

Head of Account & Business Development

Ypsomed AG

Jakob Lange is Head of Account and Business Development at Ypsomed with responsibility for all sales, customer relationships and marketing activities in the B2B Delivery Systems business.

Prior to his current role, he has held different positions within marketing and sales as well as in R&D project management. He has been with Ypsomed for more than 18 years.

Jakob holds an MSc degree in chemical engineering from the Royal Institute of Technology in Stockholm, Sweden, and a PhD in polymer science from the Swiss Federal Institute of Technology in Lausanne, Switzerland. He has written and published more than 40 peer-reviewed papers on medical devices, packaging materials, and polymers, and is a regular contributor to conferences on these topics.

DR. STEINAR MADSEN

Medical Director Department of Drug Information

Norwegian Medicines Agency

Dr. Steinar Madsen is medical director at the Norwegian Medicines Agency. He has been working with generic substitution since it was introduced in Norway in 2001 and with biosimilars since 2006. He is member and previously chair­man of the committee for generic substitution at the Agency. Dr. Madsen is also engaged in the drug information service, with a special interest in the safe and cost effective use of drugs. He is a specialist in internal medicine and cardiology and works part time as a consultant in cardiology.

Dr. Jakob Lange, CH

Head of Account & Business Development

Ypsomed AG

DR. STEINAR MADSEN

Medical Director Department of Drug Information

Norwegian Medicines Agency

Sponsors